NasdaqGM:RYTMBiotechs
Eli Lilly Stock Rally Puts Obesity Drug Shares Under The Microscope
The race to treat obesity and metabolic disease is reshaping expectations across large pharmaceutical stocks, and Eli Lilly is front and center after its Q2 earnings and outlook upgrade around Zepbound, Mounjaro and new pill Foundayo. Stronger than expected demand and higher 2026 sales guidance have sharpened investor focus on which companies are most exposed to this GLP-1 driven story. This article looks at three large-cap Healthcare stocks from a metabolic and obesity treatment screener...